Publication | Open Access

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

Relapsing-remitting Multiple SclerosisMedicineClinical NeurologyClinical TrialsNeurological ProgressPharmacotherapyNeurologyMultiple SclerosisNeuroimmunologyCcmr One